Page 11 - Kidney Cancer Research Network of Canada (KCRNC) consensus statement on the role of cytoreductive nephrectomy for patients with metastatic renal cell carcinoma

CUAJ – Consensus Statement Mason et al
KCRNC consensus: Cytoreductive nephrectomy for mRCC

11. Day D, Kanjanapan Y, Kwan E, Yip D, Lawrentschuk N, Davis ID, et al. Benefit
from cytoreductive nephrectomy and the prognostic role of neutrophil-to-
lymphocyte ratio in patients with metastatic renal cell carcinoma. Intern Med J.
2016;46:1291-7.
12. Xiao W-J, Zhu Y, Dai B, Zhang H-L, Ye D-W. Assessment of survival of patients
with metastatic clear cell renal cell carcinoma after radical cytoreductive
nephrectomy versus no surgery: a seer analysis. Int Braz J Urol. 2015;41:288-95.
13. Heng DYC, Wells JC, Rini BI, Beuselinck B, Lee J-L, Knox JJ, et al.
Cytoreductive nephrectomy in patients with synchronous metastases from renal
cell carcinoma: results from the International Metastatic Renal Cell Carcinoma
Database Consortium. Eur Urol. 2014;66:704-10.
14. Conti SL, Thomas IC, Hagedorn JC, Chung BI, Chertow GM, Wagner TH, et al.
Utilization of cytoreductive nephrectomy and patient survival in the targeted
therapy era. Int J Cancer. 2014;134:2245-52.
15. Bamias A, Tzannis K, Papatsoris A, Oudard S, Beuselinck B, Escudier B, et al.
Prognostic significance of cytoreductive nephrectomy in patients with
synchronous metastases from renal cell carcinoma treated with first-line sunitinib:
a European multiinstitutional study. Clin Genitourin Cancer. 2014;12:373-83.
16. Abern MR, Scosyrev E, Tsivian M, Messing EM, Polascik TJ, Dudek AZ.
Survival of patients undergoing cytoreductive surgery for metastatic renal cell
carcinoma in the targeted-therapy era. Anticancer Res. 2014;34:2405-11.
17. You D, Jeong IG, Ahn J-H, Lee DH, Lee J-L, Hong JH, et al. The value of
cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of
targeted therapy. J Urol. 2011;185:54-9.
18. Choueiri TK, Xie W, Kollmannsberger C, North S, Knox JJ, Lampard JG, et al.
The impact of cytoreductive nephrectomy on survival of patients with metastatic
renal cell carcinoma receiving vascular endothelial growth factor targeted therapy.
J Urol. 2011;185:60-6.
19. Margulis V, Shariat SF, Rapoport Y, Rink M, Sjoberg DD, Tannir NM, et al.
Development of accurate models for individualized prediction of survival after
cytoreductive nephrectomy for metastatic renal cell carcinoma. Eur Urol.
2013;63:947-52.
20. Abel EJ, Spiess PE, Margulis V, Master VA, Mann M, Zargar-Shoshtari K, et al.
Cytoreductive Nephrectomy for Renal Cell Carcinoma with Venous Tumor
Thrombus. J Urol. 2017;03:06.
21. Baum YS, Patil D, Huang JH, Spetka S, Torlak M, Nieh PT, et al. Elevated
preoperative neutrophil-to-lymphocyte ratio may be associated with decreased
overall survival in patients with metastatic clear cell renal cell carcinoma
undergoing cytoreductive nephrectomy. Asian J Urol. 2016;3:20-5.